Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 3,500
- 试验地点
- 107
- 主要终点
- Change of the number of enrolled subjects
研究概览
简要总结
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic/multifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.
In this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.
详细描述
The AIDA registry service is based on REDCap (Research Electronic Data Capture, project-redcap.org), a secure web application for building and managing online surveys and databases, designed to support data capture for research studies. The platform is directly accessible through the AIDA website, after inserting a personal username and password. Currently, 11 registries are available, each one dedicated to the collection of data about:
- monogenic AID
- PFAPA syndrome
- undifferentiated systemic AID (USAID)
- Behçet's disease
- Schnitzler's disease
- VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
- Still disease
- noninfectious uveitis
- noninfectious scleritis
- spondyloarthritis
- Castleman disease
The registry will pursue the following aims within the first 36 months from the start of the enrollment:
- to identify any association between clinical manifestations and gender, disease duration, body mass index and tabagism;
- to detect differences in the clinical phenotype between pediatric-onset and adult-onset patients;
- to identify the impact of different treatment approaches on clinical and laboratory disease manifestations.
Additional aims of the AIDA project, to be reached over the next 10 years, are the following:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;
- •to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and/or classification criteria;
- •to be diagnosed with undifferentiated systemic AID;
- •to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;
- •to be diagnosed with anterior or posterior non-infectious scleritis;
- •to be diagnosed with spondyloarthritis according to ASAS and/or New York criteria;
- •to be diagnosed with Castleman disease;
排除标准
- •informed consent/assent not provided by the patient and/or his/her legal representative.
结局指标
主要结局
Change of the number of enrolled subjects
时间窗: 0-36-60-120 months
This is an observational registry. The primary outcome is the increase of the number of subjects enrolled within each nosologic group.
次要结局
- Change in the overall damage score(0-36-60-120 months)
- Change in the % of patients with new organ involvement(0-36-60-120 months)
- Incidence of death or adverse events(0-36-60-120 months)
- Change in visual acuity expressed as Best Corrected Visual Acuity (BCVA)(0-36-60-120 months)
- Change in the disease activity score(0-36-60-120 months)
- Changes in height and weight percentile values for age and sex(0-36-60-120 months)
- Change in the inflammatory markers values (ESR)(0-36-60-120 months)
- Change in the overall function score(0-36-60-120 months)
- Change in articular pain measured as Visual Analogue Scale for articular Pain (VAS Pain)(0-36-60-120 months)
- Change in the inflammatory markers values (CRP and SAA)(0-36-60-120)
- Change in the % of patients experiencing fatigue(0-36-60-120 months)
- Change in the socioeconomic indicators(0-36-60-120 months)
- Change in the % of patients with fertility reduction or pregnancy complications(0-36-60-120)
研究者
Luca Cantarini
MD, PhD, Professor of Rheumatology
University of Siena
